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Abstract
Background Previous literature demonstrates the interest
of gait analysis to predict cognitive decline in old people.
Aims This pilot study aims to determine if gait speed or
gait variability is a marker able to early identify, among
mild cognitive impairment (MCI) subjects, those at risk to
develop Alzheimer’s disease (AD) in the future.
Methods 13 MCI subjects were included in 2007. Their
gait parameters (walking speed, stride length and gait fre-
quency, regularity and symmetry) were measured in 2007
and 2008 in simple task (ST) and in dual task (DT) using a
triaxial accelerometer (Locometrix). Among the 13 MCI
subjects included in 2007, 10 were assessed in 2008. So, 23
(13 in 2007 ? 10 in 2008) gait tests were collected. In
2011, MCI people were considered as ‘‘MCI?’’ when they
developed AD (between baseline and 2011) and as
‘‘MCI-’’ if they did not. Among the 23 gait tests, 15 were
from MCI? (9 gait tests in 2007 and 6 in 2008) and 8 from
MCI- (4 gait tests in 2007 and 4 gait tests in 2008). Mann–
Whitney non-parametric U test was used to compare gait
parameters of MCI? and MCI-.
Results Gait speed, symmetry and regularity were lower
in MCI? than in MCI-.
Discussion Despite the small sample size, the results
presented in this original pilot study are in line as the
infrequent previous literature related to this topic. The
authors discuss lacks and strengths of this work.
Conclusions These results suggest that both gait speed
and gait variability could be markers to early identify MCI
at risk to develop AD.




CIRS Cumulative Illness Rating Scale
DT Dual task
GDS-15 Geriatric Depression Scale—15 items
MNA Mini Nutritional Assessment
MCI Mild Cognitive Impairment
MCI? MCI who will develop AD
MCI- MCI who will not develop AD
MCR Motor cognitive risk
MMSE Mini Mental State Evaluation
ST Simple task
Introduction
Since the last 20 years, the number of studies including
instrumental gait analysis are growing, especially those
concerning the relationships between gait performances
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and cognitive functions [1, 2], the relationships between
the gait performance and the brain modifications related to
neurodegenerative process [3, 4], and the relationship
between gait performance and vascular burden [5, 6].
In this context, gait speed [7, 8] and variability of the
gait seem to be potential parameters predicting cognitive
decline and dementia in seniors [9, 10]. Performances in
these two parameters could be influenced by several con-
founders as the age [11, 12], the gait speed [12], history of
falls [13], cognitive functioning [10, 14], frail status [15]
and the walking conditions [16]. A recent study tries to
identify between these two parameters which one is the
most associated with specific cognitive functions among
MCI people [17]. But actually it remains unclear which
parameters (gait speed, gait variability or both) are most
useful to predict cognitive decline.
The goals of this prospective and exploratory study were
first, to analyze gait performance of a group of MCI pre-
senting at least a possible confounder; second, after a
3-year follow-up, to identify into this group, the MCI
patients who will develop AD and those who will not;
third, to compare gait performance obtained at baseline.
The authors hypothesize that the gait speed and the
parameters showing the variability of the gait could help
the clinician to discern earlier MCI at risk to develop AD.
Population, materials and method
Population
The MCI patients were recruited among those attending
Lie`ge University Hospital’s Memory Centre. Memory
disorders were diagnosed by standard medical imaging and
neuropsychological evaluation methods. According to
Petersen criteria [18], the diagnostic of MCI was estab-
lished when patients present a confirmed, isolated cognitive
disorder without important impact on their activities of
daily living and undergo neurological, neuropsychological
and neuro-imaging diagnostic evaluations with a clinical
dementia rating score (CDR) below 0.5 [19]. Other
exclusion criteria included mental retardation, less than
four regular years of education, cranial trauma, epilepsy,
cancer, depression, drugs abuse or any other acute organic
disease. At inclusion, none of the patients was taking any
medication likely to influence their cognitive performance.
Their score in the Mini Mental State Examination (MMSE)
[20] had to be 24/30 or more. In 2011, after a 4-year fol-
low-up, MCI considered as ‘‘MCI?’’ were diagnosed as
having probable AD according to the criteria defined by the
National Institute of Neurological and Communicative
Disorders and Stroke/Alzheimer Disease and Related
Disorders Association (NINCDS-ADRDA) [21]. All sub-
jects attending this study were assessed by a complete
neurological and neuropsychological evaluation, and with a
FDG-PET scan to provide the diagnosis.
The following medical conditions were exclusion cri-
teria: vascular stroke with motor or sensory disorder;
Parkinson’s disease; non-compensated diabetes; non-com-
pensated arterial hyper- or hypotension; any cardiac or
respiratory disease which could cause gait-limiting weak-
ness or dyspnea; a hip or knee prosthesis; arthritis or
another invalidating bone/joint disease.
The use of benzodiazepine, antidepressant or small
doses of neuroleptics (without motor repercussions) was
accepted. Patients needing glasses and/or hearing aid were
eligible but the subjects had to be completely satisfied with
the performance of these sensory aids. A medical evalua-
tion including an interview (to establish the subject’s full
personal medical history), and a comprehensive clinical
and functional examination was performed for all patients
to check for the absence of exclusion criteria and to ensure
that the gait test results and the neuropsychological
assessment would not be influenced by any organic,
affective or functional factors. Then, medical and func-
tional assessment included sex, age, body mass index (BMI
in kg/m2), Mini Nutritional Assessment (MNA) [22], co-
morbidities according to the Cumulative Illness Rating
Scale (CIRS) [23], pain evaluation using pain horizontal
analogue visual scale [24, 25], mood evaluation using the
15-items Geriatric Depression Scale (GDS-15) [26] and an
evaluation of autonomy for basic and instrumental daily
living activities using Katz scale (ADL) [27] and Lawton
scale (IADL) [28], respectively. The scores considered for
the GDS and the Lawton scale were the sum of the score
obtained divided by the number of items applied (an item
were not applied if the activity never has been done by the
subject; e.g. men never doing housework).
After this assessment, 13 MCI persons are eligible and
accept the follow-up. They were informed about the
experimental procedure and provided written inform con-
sent. The study was approved by the local ethics committee
of the University Medical Centrum of Lie`ge (Belgium).
Material
Gait analysis system
The gait analysis system used (Locometrix) is an
accelerometric method comprising an acceleration sensor,
a recording device and a computer program for processing
the acceleration signal. The sensor is composed of two
accelerometers placed perpendicularly to each other in a
plastic box as previously explained [29, 30]. The sensor’s
box is incorporated in an elastic abdominal belt, behind the
back over the L3–L4 intervertebral lumbar space (the third
Aging Clin Exp Res
123
Author's Personal Copy
lumbar vertebra level) using an elastic, abdominal belt. The
first accelerometer is aligned to the mediolateral axis of the
body; the second is aligned to the cranio-caudal axis.
Acquisition frequency of the signal was of 50 Hz. The
system can record continuously for 10 min. The recorded
signals are transferred to a laptop computer using a transfer
program operated under windows 98, formatted in files and
analyzed by software developed in the MATLAB 5 envi-
ronment. The data are transferred to a computer for sta-
tistical spreadsheet analysis.
Gait analysis
As explained previously [31, 32], during the test, the sub-
ject walks up and back along a straight 40 m corridor, free
of obstacles or visual/auditory distractions, at a freely
chosen pace and cadence, and using their usual walking
shoes avoiding high heels. Two timing lines are located
5 m after the starting line and 5 m before the 40 m line,
respectively, allowing the time measurement on 30 m
walk. First, subjects were asked to walk in simple task at
preferred walking speed. The same day, subjects were
asked to walk in dual task condition, again at preferred
walking speed and without prioritization instructions.
According to Professor O. Beauchet, we choose a count-
down from 50 as cognitive task during dual task because
this is the additional cognitive task that perturbs most of the
gait parameters in a dual-task paradigm [33].
Data processing
As explain before [29, 30], two periods of steady state
walking of 20.48 s was selected from each subject. The
first one was concerning simple task (ST) conditions and
the other one concerned dual task (DT) conditions. Each
period (of 20.48 s) contained about 1024 acceleration
measurements and provided an optimal calculation time.
This period correspond to 19–21 gait cycles. Using the
walking time and according to the software (using fast
Fourier transformation), the following gait variables are
available:
– Gait speed, measured using a timing line and expressed
in meters/second.
– Stride frequency or number of cycles per second (Hz),
calculated from the cranio-caudal acceleration follow-
ing application of a Fourier transform.
– Stride length, deduced from the equation [speed = fre-
quency 9 stride length] and expressed in meters.
– Regularity, measured by the similarity (in terms of
duration and amplitude) of the shape of cranio-caudal
acceleration curves from steps and strides. This
parameter is expressed in absolute value.
– Symmetry, defined as the similarity (in terms of
duration and amplitude) of the shape of cranio-caudal
acceleration curves when focusing on the right and left
steps. This parameter is expressed in absolute value.
As explain before [29, 30], symmetry and regularity
were calculated based on two different coefficients, C1 and
C2. These coefficients are calculated based on the auto
correlation of the vertical accelerating signal. C1 represents
the correlation between the vertical accelerating signals
considering one step to the following step (a step is a part
of a stride and a stride includes a left step and a right step).
In fact, each step is correlated to the following step (au-
tocorrelation) and C1 shows the mean value of all these
autocorrelations. C2 represents the correlation between the
vertical accelerating signals considering all successive
strides. The symmetry is calculated as C1/C2 9 100. The
regularity is calculated as (C1 ? C2) 9 100.
All subjects walked first time in ST and after in DT.
From 2007 until 2011, all subjects were yearly assessed
by neuropsychological testing as used in the memory
clinic. Their cognitive status was classified according to the
neurological and neuropsychological criteria previously
detailed. In 2011, according to the neurological diagnosis,
subjects were considered as ‘‘MCI?’’ when they developed
AD between 2007 and 201,1 and as ‘‘MCI-’’ if they did
not. According to this distribution, 15 gait tests were
coming from MCI? patients and 8 gait tests were coming
from MCI- patients. Among the 23 gait tests, 15 were
from MCI? (9 gait tests in 2007 and 6 in 2008) and 8 from
MCI- (4 gait tests in 2007 and 4 gait tests in 2008). In the
pilot study, we considered each gait testing as an individual
gait test and not as a serial test on the same person. Then,
we performed statistical analysis concerning 23 walking
tests. We use the Mann–Whitney U test, a non-parametric
statistical test to do the comparison between the mean gait
performance of ‘‘MCI?’’ and ‘‘MCI-’’ patients. A p value
\0.05 was considered significant throughout and data
normality was confirmed using the Lilliefors test.
Results
Main medical characteristics, functional and neuropsy-
chological performances from MCI subjects at inclusion
are presented in the Table 1.
As shown in Table 2, MCI? patients have a significant
statistical difference with MCI- patients concerning the
gait speed (in ST and DT) and concerning the symmetry in
DT. Gait speed and symmetry are higher in MCI- patients
than in MCI? patients.
All MCI people show worse gait performances in DT
compared to ST.
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Moreover, the regularity is lower in MCI? than in
MCI-, but the difference is not statistically significant.
Discussion
The results of this pilot study highlight the interest of
accelerometric measurements of gait to help the early
detection of MCI at risk of developing AD, especially
according to the gait speed and its symmetry. According to
the recent literature, we would discuss the interest to study
the gait speed, the use of a DT and the interest to consider
the variability of gait.
Concerning the gait speed, in this study, MCI patients
who develop AD have a lower gait speed (in ST and in DT)
than those who do not. Our results are convenient with
those obtained in different cohort included in prospective
study with dementia as clinical outcome [2, 7, 8]. Actually,
these previous studies highlight the interest of gait speed
essentially concerning the risk of vascular dementia.
According to JM Hausdorff [34], imaging studies and
pathology studies highlight the presence of vascular burden
and AD lesions even in older people without clinical signs
of dementia. According to Verghese [35], studying gait
speed of an old person already presenting a mild cognitive
decline could help to detect people at risk to develop
dementia. The main idea of the concept of MCR is that the
motor dysfunction and the cognitive decline are both sign
of the same pathological process including diffuse lesions
in the brain leading to dementia. This MCR concept has
already shown its association with cognitive decline in a
wider cohort [36]. Unfortunately and according to our
knowledge, no published data shows a strong relation be-
tween slow gait speed and specific risk to specifically
Table 1 Main characteristics of
MCI at inclusion
Medical and functional variables MCI?, N = 9 (mean ± SD) MCI-, N = 4 (mean ± SD)
Age 74.44 ± 4.16 70.00 ± 2.16
Sex 4 women 2 women
MNA 19.87 ± 7.00 23.25 ± 6.86
CIRS 5.00 ± 2.60 5.50 ± 3.42
Visual analog scale pain 0.89 ± 2.67 0.50 ± 1.00
GDS 0.13 ± 0.14 0.19 ± 0.02
ADL 6 ± 0.00 6 ± 0.00
IADL 0.26 ± 0.03 0.26 ± 0.00
MMSE 26.11 ± 1.45 27.25 ± 1.70
Mattis, total score 133.11 ± 5.67 137.50 ± 5.20
Mattis, attentional score 35.78 ± 1.09 36.00 ± 1.15
Mattis, initiation score 32.89 ± 3.56 36.00 ± 1.41
Mattis, construction score 5.78 ± 0.44 6.00 ± 00
Mattis, conception score 37.22 ± 1.48 37.25 ± 1.71
Mattis, memory score 21.44 ± 3.28 22.25 ± 2.28
GrB, free recall total score 15.77 ± 8.13 18.50 ± 8.70
GrB, cued free recall 35.11 ± 8.82 38.00 ± 9.83
GrB, delay free recall 4.33 ± 2.45 5.50 ± 4.36
GrB, delay cued free recall 12.00 ± 2.78 13.00 ± 3.46
Table 2 Gait performances in simple task (ST) and dual task (DT) of MCI? patients and MCI- patients and respective p value obtained using
the U test of Mann–Whitney
Gait’s parameters Gait of MCI? (N = 15), mean ± SD Gait of MCI- (N = 8), mean ± SD p value
Speed in ST (m/s) 1.15 ± 0.13 1.29 ± 0.10 0.017
Regularity in ST 286.20 ± 37.45 298.0 ± 22.46 0.196
Symmetry in ST 219.47 ± 36.92 269.13 ± 69.86 0.061
Speed in DT (m/s) 1.01 ± 0.18 1.18 ± 0.12 0.036
Regularity in DT 220.67 ± 254.88 254.88 ± 32.86 0.129
Symmetry in DT 220.60 ± 66.78 201.13 ± 28.03 0.039
Bold values indicate p\ 0.05
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develop AD. Then, a strict comparison of our results to
previous literature is still limited.
Concerning the use of a DT, in this study, all MCI
people show worse gait performances in DT comparing in
ST. These results are similar to those found by Montero-
Odasso and Muir using a GaitRite system, and showing the
importance of executive function and working memory
considering gait performances in DT [37, 38].Concerning
the variability of the gait, and as explained previously, the
parameters available with the Locometrix are the regu-
larity showing the shape of cranio-caudal acceleration
curves from steps and strides, and the symmetry showing
the similarity (in terms of duration and amplitude) of the
shape of cranio-caudal acceleration curves when compar-
ing right and left steps. In the actual literature [11, 39], the
terms used to translate the variability (or the less-regular-
ity) of the gait are more often the ‘‘variability of the stride
length’’ or the ‘‘variability of the stride time’’ or the
‘‘variability of the step width’’ as expressed in terms of the
coefficients of variation for each term [CV or CoV calcu-
lated as (SD/mean) 9 100]. According to Moe-Nilssen
[40], step time variability seems to be correlated with
vertical (cranio-caudal) interstep trunk variability.
Considering that Locometrix, regularity is calculated on
cranio-caudal accelerations curves, and considering find-
ings of Moe-Nilssen, the authors allow themselves that the
regularity and the symmetry obtained by the Locometrix
could represent a translation of the ‘‘step time variability’’.
In this study, MCI? group has a lower regularity than
MCI- group. And overall, MCI? group shows a
decreasing regularity when walking in DT. Unfortunately,
and even if this decreasing regularity in DT seems to be
important, the difference between the two groups remains
statistically non-significant, probably because of the sam-
ple size.
The second parameter showing the variability of the gait
using this accelerometer is symmetry. In our study, MCI?
group presents in DT a symmetry significantly lower than
MCI- group. This observation can be explained by the
way used by the software to obtain the symmetry. Indeed,
symmetry is calculated as C1/C2 9 100. So the symmetry
can increase in case of an increase of C1 or in case of a
decreasing C2. This second possibility is probably the best
explanation of this decrease of symmetry in DT.
Moreover, the fact that this decrease in C2 is more
‘‘numerically important’’ in terms of symmetry than in
terms of regularity, is probably linked to the mean to obtain
the regularity [(C1 ? C2) 9 100], decreasing the relative
importance of a decrease of C2.
These results considering the regularity and the sym-
metry are in the same line that other studies showing an
increasing variability of the gait in MCI people at risk to
develop AD [2, 17].
This study has a number of limitations and our results
have to be considered with caution.
First, the size of the sample is reduced because of the
size of the only memory clinic attending, the number of
exclusion criteria and the long time of the follow-up. The
results presented have to be considered with caution.
Second, a comparison would be interesting between the
four sub-types of MCI (anamnestic single domain MCI,
anamnestic multiple domain MCI, executive single domain
MCI and executive multiple domain MCI) but unfortu-
nately this cohort included mainly anamnestic MCI whose
usually does not present a high level of gait modification.
However, considering the fact that FDG-PET scanner
realized at inclusion confirmed the neurodegenerative
process occurring in the brain and the high level of AD
development in this cohort (9 MCI/13 in 3 years), we could
consider these MCI particularly ‘‘at risk’’ to develop AD
and probably presenting widespread brain lesions. This ‘‘at
risk’’ status could probably explain the early gait
modifications.
Third, we do not know the time of conversion from MCI
to AD, because we do not consider when they develop AD.
Finally, only MCI developing AD was considered. MCI
developing other dementia, for example, vascular dementia
or frontotemporal dementia were excluded.
The strengths of this pilot study include a population
strictly selected. Exclusion criteria included a lot of
potential confounders as orthopedic prosthesis, previous
falls, depression, sedative medication, previous neurologic
pathology, clinical neurologic disorders or abnormalities.
All subjects attending this study were assessed by a com-
plete neurological, neuropsychological and with a brain
FDG-PET scan to confirm the MCI neurodegenerative
syndrome. MCI patients included by this way were free of
confounders usually met in older people and they were
more prompt to develop AD.
Moreover, the length of the straight long corridor used
(40 m) allows guaranteeing strong conditions to reliably
assess the gait parameters. Indeed, we exclude more than
the first 2.5 m of walking to be sure to achieve the steady
state walking as recommended by Lindeman [41] and with
the guidelines for clinical applications of spatio-temporal
gait analysis in older adults from the European Gait Rite
Network [42]. Regarding the assessment of gait variability,
the same author recommends walking at least 20 gait
cycles. In our study, the mean cadence was 0.89 ± 0.05 for
the MCI who will develop AD and the cadence of those
who will not develop AD was 0.95 ± 0.04. So, by con-
sidering and analyzing period of 20, 48 s., all subjects
walked at least 20 gait cycles as recommended [41].
Furthermore these results are really interesting regarding
their statistical significance using a non-parametric statisti-
cal test.
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Further research are needed to confirm these results in
bigger sample, including not only amnestic MCI but also
executive MCI, and not only considering AD as the only
outcome but rather all the cognitive evolutions.
Conclusion
In this prospective and exploratory study, MCI who will
develop AD have lower gait speed, lower symmetry and
lower regularity in DT than those who will not develop
AD. According with previous literature, and even if this
results have to be considered with caution, the gait speed
and the parameters showing the variability of gait seem to
be important, considering the risk of developing dementia
among MCI people.
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